<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results at 1 Year with CoreValve TAVR in Patients with Symptomatic Aortic Stenosis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Transcatheter aortic valve replacement (TAVR) has become a treatment option for patients with severe aortic stenosis who either are not surgical candidates or are at high risk for surgical complications. The results from the US CoreValve pivotal trials support the safety and efficacy of the CoreValve prosthesis in these patient populations. This article discusses detailed data from the CoreValve trials</style></abstract><number><style face="normal" font="default" size="100%">24</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>